{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:56:28Z","timestamp":1792292188238,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most women with advanced breast cancer have skeletal metastases. Radium-223 is an alpha-emitting radionuclide that selectively targets areas of bone metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two double-blind, placebo-controlled studies of radium-223 were conducted in women with hormone receptor-positive (HR+), bone-predominant metastatic breast cancer. All patients received endocrine therapy (ET), as a single agent of the investigator\u2019s choice (Study A) or exemestane\u2009+\u2009everolimus (Study B). Patients were randomized to receive radium-223 (55\u00a0kBq\/kg) or placebo intravenously every 4\u00a0weeks for six doses. Accrual was halted following unblinded interim analyses per protocol amendments, and both studies were terminated. We report pooled analyses of symptomatic skeletal event-free survival (SSE-FS; primary endpoint), radiologic progression-free survival (rPFS) and overall survival (OS; secondary), and time to bone alkaline phosphatase (ALP) progression (exploratory).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 382 patients were enrolled, and 196 SSE-FS events (70% planned total) were recorded. Hazard ratios (95% confidence intervals) and nominal\n                      <jats:italic>p<\/jats:italic>\n                      values for radium-223\u2009+\u2009ET versus placebo\u2009+\u2009ET were: SSE-FS 0.809 (0.610\u20131.072),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.1389; rPFS 0.956 (0.759\u20131.205),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.7039; OS 0.889 (0.660\u20131.199),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.4410; and time to bone ALP progression 0.593 (0.379\u20130.926),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0195. Radium-223- or placebo-related treatment-emergent adverse events were reported in 50.3% versus 35.1% of patients (grade 3\/4: 25.7% vs. 8.5%), with fractures\/bone-associated events in 23.5% versus 23.9%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with HR+\u2009bone-metastatic breast cancer, numeric differences favoring radium-223\u2009+\u2009ET over placebo\u2009+\u2009ET for the primary SSE-FS endpoint were suggestive of efficacy, in line with the primary outcome measure used in the underlying phase 2 studies. No similar evidence of efficacy was observed for secondary progression or survival endpoints. Adverse events were more frequent with radium-223\u2009+\u2009ET versus placebo\u2009+\u2009ET, but the safety profile of the combination was consistent with the safety profiles of the component drugs.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Clinical trial registration numbers<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>Study A: NCT02258464, registered October 7, 2014.<\/jats:p>\n                    <jats:p>Study B: NCT02258451, registered October 7, 2014.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-023-07147-z","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T13:01:51Z","timestamp":1703077311000},"page":"249-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials"],"prefix":"10.1007","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-4814","authenticated-orcid":false,"given":"Hope S.","family":"Rugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-6908","authenticated-orcid":false,"given":"Catherine H.","family":"Van Poznak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1434-9460","authenticated-orcid":false,"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-6272","authenticated-orcid":false,"given":"Iwona","family":"Danielewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-6419","authenticated-orcid":false,"given":"Soo Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5196-5908","authenticated-orcid":false,"given":"Mario","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannie Y. K.","family":"Chik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estela","family":"Vega Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6811-9476","authenticated-orcid":false,"given":"Bj\u00f8rn","family":"Naume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0881-9371","authenticated-orcid":false,"given":"Etienne","family":"Brain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6477-4281","authenticated-orcid":false,"given":"Jonathan M.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6883-6678","authenticated-orcid":false,"given":"Deise","family":"Uema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker J.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-1043","authenticated-orcid":false,"given":"Robert E.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"7147_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13063-019-3643-6","volume":"21","author":"R Coleman","year":"2020","unstructured":"Coleman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I, Brown S (2020) CApecitabine plus radium-223 (Xofigo) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB\/IIA randomised controlled trial. Trials 21:89. https:\/\/doi.org\/10.1186\/s13063-019-3643-6","journal-title":"Trials"},{"key":"7147_CR2","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland \u00d8, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K (2020) Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol 31:1650\u20131663. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.019","journal-title":"Ann Oncol"},{"key":"7147_CR3","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.2147\/DDDT.S122417","volume":"11","author":"E Deshayes","year":"2017","unstructured":"Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houede N (2017) Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther 11:2643\u20132651. https:\/\/doi.org\/10.2147\/DDDT.S122417","journal-title":"Drug Des Devel Ther"},{"key":"7147_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall\u2019Oglio M, Franzen L, Coleman R, Vogelzang NJ, O\u2019Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, Investigators ALSYMPCA (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"key":"7147_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1517\/14740338.2015.1045874","volume":"14","author":"S Nilsson","year":"2015","unstructured":"Nilsson S (2015) Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Expert Opin Drug Saf 14:1127\u20131136. https:\/\/doi.org\/10.1517\/14740338.2015.1045874","journal-title":"Expert Opin Drug Saf"},{"key":"7147_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/annonc\/mdw065","volume":"27","author":"S Nilsson","year":"2016","unstructured":"Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O\u2019Sullivan JM, Reuning-Scherer J, Shan M, Zhan L, Parker C (2016) Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 27:868\u2013874. https:\/\/doi.org\/10.1093\/annonc\/mdw065","journal-title":"Ann Oncol"},{"key":"7147_CR7","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/cam4.2780","volume":"9","author":"NT Ueno","year":"2020","unstructured":"Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA (2020) Phase II study of radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med 9:1025\u20131032. https:\/\/doi.org\/10.1002\/cam4.2780","journal-title":"Cancer Med"},{"key":"7147_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s00259-019-04475-5","volume":"47","author":"S Dizdarevic","year":"2020","unstructured":"Dizdarevic S, McCready R, Vinjamuri S (2020) Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice. Eur J Nucl Med Mol Imaging 47:192\u2013217. https:\/\/doi.org\/10.1007\/s00259-019-04475-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7147_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-211152","author":"A Takalkar","year":"2015","unstructured":"Takalkar A, Paryani B, Adams S, Subbiah V (2015) Radium-223 dichloride therapy in breast cancer with osseous metastases. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2015-211152","journal-title":"BMJ Case Rep"},{"key":"7147_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10549-014-2939-1","volume":"145","author":"R Coleman","year":"2014","unstructured":"Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P (2014) A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat 145:411\u2013418. https:\/\/doi.org\/10.1007\/s10549-014-2939-1","journal-title":"Breast Cancer Res Treat"},{"key":"7147_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.7417\/CT.2019.2100","volume":"170","author":"RP Costa","year":"2019","unstructured":"Costa RP, Tripoli V, Princiotta A, Murabito A, Licari M, Piazza D, Verderame F, Pinto A (2019) Therapeutic effect of RA223 in the management of breast cancer bone metastases. Clin Ter 170:e1\u2013e3. https:\/\/doi.org\/10.7417\/CT.2019.2100","journal-title":"Clin Ter"},{"key":"7147_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1053\/j.semnuclmed.2015.10.012","volume":"46","author":"R Coleman","year":"2016","unstructured":"Coleman R (2016) Treatment of metastatic bone disease and the emerging role of radium-223. Semin Nucl Med 46:99\u2013104. https:\/\/doi.org\/10.1053\/j.semnuclmed.2015.10.012","journal-title":"Semin Nucl Med"},{"key":"7147_CR13","doi-asserted-by":"publisher","first-page":"PS14-01","DOI":"10.1158\/1538-7445.Sabcs20-ps14-01","volume":"81 (Suppl)","author":"RE Coleman","year":"2021","unstructured":"Coleman RE, Fried G, Kim S-B, Kuchuk I, Kiesl D, Ramos M, Sohn J, Siegel J, Li R, Uema D, Wagner V, Rugo HS (2021) Radium-223 in women with HR-positive bone-metastatic breast cancer receiving endocrine therapy: international phase 2, randomized, double-blind, placebo-controlled trial. Cancer Res. https:\/\/doi.org\/10.1158\/1538-7445.Sabcs20-ps14-01","journal-title":"Cancer Res"},{"issue":"Suppl 3","key":"7147_CR14","doi-asserted-by":"publisher","first-page":"182P","DOI":"10.1016\/annonc\/annonc894","volume":"33","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Drumea K, Lee SC, Campone M, Van Poznak C, Neven P, Vega Alonso E, Naume B, Siegel JM, Li R, Uema D, Wagner VJ, Coleman RE (2022) Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+\/HER2\u2212) metastatic breast cancer (MBC) with bone metastases: a phase 2 study. Ann Oncol 33(Suppl 3):182P. https:\/\/doi.org\/10.1016\/annonc\/annonc894","journal-title":"Ann Oncol"},{"key":"7147_CR15","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cort\u00e9s J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623\u20131649. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.010","journal-title":"Ann Oncol"},{"key":"7147_CR16","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1200\/jco.21.01392","volume":"39","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS (2021) Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol 39:3959\u20133977. https:\/\/doi.org\/10.1200\/jco.21.01392","journal-title":"J Clin Oncol"},{"key":"7147_CR17","doi-asserted-by":"publisher","first-page":"100442","DOI":"10.1016\/j.jbo.2022.100442","volume":"35","author":"M Winter","year":"2022","unstructured":"Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J, Taylor C, Eastell R, Murden G, Brown SR, Rathbone E, Brown J (2022) A phase IB and randomised phase IIA trial of CApecitabine plus radium-223 (Xofigo\u2122) in breast cancer patients with BONe metastases: CARBON trial results. J Bone Oncol 35:100442. https:\/\/doi.org\/10.1016\/j.jbo.2022.100442","journal-title":"J Bone Oncol"},{"key":"7147_CR18","doi-asserted-by":"publisher","first-page":"896301","DOI":"10.3389\/fonc.2022.896301","volume":"12","author":"H Houssiau","year":"2022","unstructured":"Houssiau H, Duhoux FP, Fran\u00e7ois D, Seront E (2022) Radium-223 as an additional therapeutic strategy in highly selected patients with metastatic breast cancer: a case report. Front Oncol 12:896301. https:\/\/doi.org\/10.3389\/fonc.2022.896301","journal-title":"Front Oncol"},{"key":"7147_CR19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","volume":"19","author":"R Wang","year":"2019","unstructured":"Wang R, Zhu Y, Liu X, Liao X, He J, Niu L (2019) The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19:1091. https:\/\/doi.org\/10.1186\/s12885-019-6311-z","journal-title":"BMC Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07147-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07147-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07147-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T11:19:37Z","timestamp":1710760777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07147-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["7147"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07147-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2205394\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"2 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HSR: Grants to institution from Astellas, AstraZeneca, Ayala, Boehringer Ingelheim, Daiichi, Gilead, Lilly, Macrogenics, Merck, Novartis, Pfizer, Polyphor, Roche, Seattle Genetics, and Sermonix; honoraria from Mylan, NAPO, Puma, and Samsung. CVP: Research grant from Bayer for a study outside of the one associated with this manuscript; royalties from UpToDate; board member (unpaid) of Cancer and Bone Society, an independent organization that promotes international collaborations within the cancer and bone field in both clinical and basic research. PN: Research funding from Kom op Tegen Kanker; consulting fees from AstraZeneca, Lilly, Novartis, Pfizer, and Roche; consulting or advisory roles for Lilly, Novartis, Pfizer, and Roche. ID, YKC, EVA, BN: No conflicts to disclose. SCL: Research grants from ACT Genomics, Eisai, Pfizer, and Taiho; consulting\/advisory roles for, and payment\/honoraria from, AstraZeneca, Daiichi-Sankyo, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, and Roche; travel\/meeting attendance support from Pfizer and Roche. MC: Payment and\/or honoraria from Amgen, Gilead, GSK, Merck Sharp & Dohme, Novartis, Pfizer, and Seagen (to institution) and from Lilly, Pierre Fabre, and Sanofi (to self). EB: Consulting fees from Daiichi-Sankyo, Pfizer, and Sandoz; payment and\/or honoraria from Eli Lilly, Pfizer, and Seagen; travel\/meeting attendance support from Pfizer and Sandoz; consultancy\/advisory role for Daiichi-Sankyo. JMS: Employee of Bayer; stock ownership in Bayer AG; leadership and\/or committee roles in Pharmaceutical Industry Working Group on Estimands in Oncology, Society for Clinical Biostatistics Subcommittee for Statistics in Regulatory Affairs, and American Statistical Association. RL, DU, VW: Employee of Bayer. REC: Consulting fees from Sanofi; payment\/honoraria from Amgen and Beigene; patent for MAF gene test and stock options with Inbiomotion; consultancy\/advisory role for AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocols and all protocol amendments were reviewed and approved by each study site\u2019s independent ethics committee or institutional review board. The studies were conducted in accordance with all local legal and regulatory requirements and with the principles in the Declaration of Helsinki and the International Council for Harmonisation guideline E6: Good Clinical Practice.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients signed an informed consent form before participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}